Welcome to our dedicated page for Nektar Therapeutics news (Ticker: NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics stock.
Nektar Therapeutics reports developments as a clinical-stage biotechnology company developing immunology therapies for autoimmune and chronic inflammatory diseases. Company news centers on rezpegaldesleukin, also known as REZPEG or NKTR-358, a regulatory T cell stimulator evaluated across disease areas including atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus.
Recurring updates also cover Nektar's preclinical pipeline, including TNFR2 antibody and bispecific programs NKTR-0165 and NKTR-0166, and the modified hematopoietic colony stimulating factor protein NKTR-422. Financial results, public equity offerings, shelf-registration activity, employee inducement grants, and other capital and governance actions are regular news themes for NKTR.
Nektar Therapeutics (NKTR) will announce its financial results for the first quarter of 2024 on May 9, 2024, after the close of U.S.-based financial markets. Howard Robin, President and CEO, will host a conference call to review the results. The press release and webcast link will be available on the Nektar website. Conference call replay will be accessible until June 9, 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.